YOUR CART
- No products in the cart.
Subtotal:
$0.00
In The News
Medium Magazine- Alleh Lindquist of FloraWorks: Five Things I Wish Someone Told Me Before I Became A CEO
Cannabis Equipment News - Insider Q&A: Americans Don’t Get Enough Sleep; Cannabis Can Fix That
The market barriers and regulatory hurdles CBN faces as a sleep aid, other cannabinoids that show promise and predictions for the therapeutic-use cannabinoid market.
Skunk Magazine - Digging Deeper with Alleh Lindquist, CEO of FloraWOrks
Trend Hunter - Floraworks' Ultra-Pure Cannabinol is Clinically Proven
FloraWorks Completes $2.25M Series-A Financing For Cannabinoid Research
FloraWorks, a company focused on rare and novel cannabinoids in the field of cannabinoid therapeutics, recently concluded a $2.25 million Series-A funding round. Notable investors in this round included Bonaventure Equity LLC, a leading life sciences venture capital firm, as well as the ArcView Group, a renowned player in the cannabis and hemp industry, alongside a high-net-worth individual.
Portland Business Journal: THE RISE, FALL AND REIMAGINING OF HEMP
How Oregon growers are surviving a market collapse.
FloraWorks Holdings Inc., in Milwaukie, has found a way to turn hemp oil into CBN, a cannabinoid that naturally develops from THC as weed grows old. Because FloraWorks makes it from hemp and it contains no THC of any sort, their product can go into any market.
CBN HAS BECOME THE LEADING GROWTH CATALYST IN THE CANNABIS EDIBLE MARKET
FloraWorks has published their CBN Market Report Q1 2021 providing early insight into the widespread consumer adoption for CBN-infused products.
Consumer data shows that CBN now represents the top selling edible products in Oregon and California’s cannabis markets. To learn more, View Press Release & Download Full CBN Market Report
NBC LX News With FloraWorks CEO Alan Ridgeway
Tabitha Lipkin and Alan Ridgeway talk about CBN
This week Alan Ridgeway, Co-Founder and CEO at FloraWorks joined Tabitha Lipkin on NBC LX to talk about Cannabinol. He shared how FloraWorks is helping companies develop new products as well where to find a consumer version of the FloraWorks tinctures.
THE CANNABIS CONVERSATION - EPISODE #79
Investigating CBN with Alan Ridgeway, Co-Founder and CEO at FloraWorks
This week we’re joined by Alan Ridgeway, Co-Founder and CEO at FloraWorks – a Canadian hemp refinement laboratory offering specialized cannabinoid formulations. Together, we explore one of the ‘minor’ cannabinoids – CBN. We take a look at its incredible therapeutic properties, mechanism of action, and its potential as a market disruptor.
FORBES
Seven Intrinsic Questions With CEO Of FloraWorks: Alan Ridgeway
“I truly believe this molecule (CBN) has the potential to be an important wellness product that can help a lot of people and I’m extremely excited to work with the team we have at FloraWorks to bring it to market.”
– Alan Ridgeway
YAHOO FINANCE
Also Known as “The Sleep Cannabinoid”, Cannabinol (CBN) Is Now Available in Commercial Quantities
This rare cannabinoid is taking the wellness and CBD markets by storm as new research and anecdotal evidence expands.
PORTLAND BUSINESS JOURNAL
This Oregon company is betting on the next next big thing in hemp.
Milwaukie startup thinks it’s cracked the code on an elusive cannabinoid, CBN.